A detailed history of Advantage Alpha Capital Partners LP transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 35,082 shares of FOLD stock, worth $289,426. This represents 0.06% of its overall portfolio holdings.

Number of Shares
35,082
Holding current value
$289,426
% of portfolio
0.06%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 13, 2025

BUY
$5.64 - $8.0 $197,862 - $280,656
35,082 New
35,082 $201,000

Others Institutions Holding FOLD

About AMICUS THERAPEUTICS, INC.


  • Ticker FOLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 280,497,984
  • Market Cap $2.31B
  • Description
  • Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...
More about FOLD
Track This Portfolio

Track Advantage Alpha Capital Partners LP Portfolio

Follow Advantage Alpha Capital Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advantage Alpha Capital Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Advantage Alpha Capital Partners LP with notifications on news.